Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07103057 · ClinicalTrials.gov registry record
VIZ ACCESS HCM - Multi-Site Registry
A clinical trial of Hypertrophic Cardiomyopathy, sponsored by Viz.ai.
- Recruiting
- Registry status
- 500
- Enrollment target
- 3
- Study locations
NCT07103057: Recruiting study of Hypertrophic Cardiomyopathy, sponsored by Viz.ai.
NCT07103057 is a study of Hypertrophic Cardiomyopathy that is actively recruiting participants, run by Viz.ai. The registered enrollment target is 500 participants, below the 1,301-participant average among 10 other Hypertrophic Cardiomyopathy trials with a reported enrollment target (62% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07103057, a study of Hypertrophic Cardiomyopathy, is actively recruiting participants, sponsored by Viz.ai.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 3
- Study locations
Study Summary
To describe the clinical, economic, and population characteristics of newly diagnosed, previously diagnosed, and suspected patients evaluated by Viz HCM. HCM is underdiagnosed in the community and AI algorithms have been developed as screening tools. However, it is not well understood how to best integrate AI screening tools and their potential impact.
Primary Outcome
To describe the clinical characteristics of patients who were alerted for suspected HCM by an AI-based ECG tool and newly diagnosed, previously diagnosed, or suspected for HCM.
Conditions Studied
Interventions
- DEVICE Viz HCM
Study Locations (3)
Georgia
- Emory University - Atlanta
Illinois
- North Shore University Health System - Evanston
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-06-13 |
| Est. Completion | 2028-12 |
What NCT07103057 shows while recruiting
NCT07103057 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 1,301-participant average among 10 other Hypertrophic Cardiomyopathy trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Hypertrophic Cardiomyopathy appearing as the primary indexed condition, and to 1 intervention - of which Viz HCM is the first listed.
NCT07103057 reports a single indexed study location in Georgia, Illinois, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07103057 about?
NCT07103057 is a clinical study titled "VIZ ACCESS HCM - Multi-Site Registry". To describe the clinical, economic, and population characteristics of newly diagnosed, previously diagnosed, and suspected patients evaluated by Viz HCM. HCM is underdiagnosed in the community and AI algorithms have been developed as screening tools. However, it is not well understood how to best in...
What is the current status of trial NCT07103057?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2025-06-13. Estimated completion is 2028-12.
What conditions does trial NCT07103057 study?
This clinical trial studies the following conditions: Hypertrophic Cardiomyopathy.
What interventions are being tested in trial NCT07103057?
The interventions under investigation include: Viz HCM (DEVICE).
Who is sponsoring clinical trial NCT07103057?
This trial is sponsored by Viz.ai, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07103057 being conducted?
This trial has 3 study locations across Georgia, Illinois, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertrophic Cardiomyopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07103057's enrollment target sits among peer trials
500 4th of 10 higher than 7 of 10 other Hypertrophic Cardiomyopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertrophic Cardiomyopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cardiovascular Multimodality Imaging Study
RECRUITING
-
Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy
RECRUITING · NA
-
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
RECRUITING · Phase 1
-
Mavacamten Pregnancy Surveillance Program
RECRUITING
-
Pediatric Cardiomyopathy Mutation Analysis
RECRUITING
-
HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI